Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hello Surf, Did you notice back in mid-jan, news came out that the CEO built himself in a 12 month parachute at 2.99 times his previous 12 month salary? And the CFO gets a year in pay.
For about anything except death, and cause.
Funny how they did this after they were talking about shopping the company around during their last cc, or being open to deals, that kind of thing. I posted about it during the cc.
Anyway, I took the Jan. filings to mean that they wanted a piece of the pie should the company change hands, or at least a "locked in" severance package. Maybe as they were getting closer to a deal?????????????
It's old news so I didn't post the story, but the link to the yahoo news is here:
http://biz.yahoo.com/e/080117/snus8-k.html
Just curious if you caught it?
Take Care.
Do you know the date for that meeting? You likely posted it somewhere, but i missed it.
Take Care.
Seems like 3'rd or 4th quarter last year, you could almost bank on a bump from a conference, or at least it seemed that way. Then came the pullback and nothing would move them. Now it will be interesting to see how they are treated.
Take Care.
Thanks Surf, I like they are going to present on the 12th. Last Monday/week ago, I bought 100 options on ZMH, who were due to present on Wed. Then next day they pre-announce they were going to beat earnings, and the stock ran 10, options up 4-500%. So I am all over watching companies due to speak!
Take Care.
Thanks Surf, I am way over 6 figures in SNUS now. That .88 in expected cash for 01/08, sure looks good against .40 share selling price! Still way over 70% cash overall to pick and choose a few going forward. Sold last non-ira cor today. Nice trade overall.
Will check out the other 2 you mentioned in the am, thanks.
Have a great night and enjoy those idmi profits
Take Care.
Sold off my remaining, non IRA Cor shares shortly after my last posting to you. That post got me thinking that 16-50% lock in's might look pretty good for profit this year.
I still have Cor in two IRA's, half full each, along with, IDMI, no kidding. Now that's some news COR could use
OT- Aiming4, were you still in IDMI? Surf was selling shares at the close he got at .61 not long ago, Yikes!
Take Care.
we sure are heading that way
+215%
Thanks for keeping this board going surf. I just checked two of my IRA's, and both were half full of IDMI. I knew I had some, but it was a pleasant surprise.
Are you taking this day by day, have a target, or perhaps you have already taken some off the table, like a 1/3?
Thanks again,
Take Care.
Hello food4thought, Great run up in Cor.
No regrets here, but of course I wish I had those shares to sell in here, but who wouldn't? I am glad I had them to sell when I did. I try to protect principle as often as possible. Sounds crazy to be in biotech with that attitude, I know, but I love the action, and I try to buy low.
If Cor, or any stock loses 50%, then I have to go out and find another that gains 100% just to break even. That is not an easy thing to do in my experience. I have kept a streak alive with Cor that I have had for a lot of years, that I made money in it yet again......both for 2007, and 2008, unless I get stupid. I am currently accumulating a position in another biotech, working toward 250k shares.... trading at less than half its cash.
Not many here have real profits in cor, unless they sell and take them. I likely will sell my remaining shares in the run up to the RD decision, maybe soon. Cor will need money, things that look rosy now, may not in the months to come. I don't really see much of a bounce if Cor gets positive RD results, just my opinion.
It has had us thinking it would really jump on positive news before, when in fact the news was already priced into it by the time the news comes around. We have seen what happens when the news is bad..... Most biotech's fail, it's a long list.
Anyway, this run up has been a long time coming, enjoy and congrats on sticking it out, also not an easy thing to do
Take Care.
The pipe happens unless someone wants to pony up some "partnering" money.
With the number of shares out, if Cor doesn't want to raise funds at low prices, they can reverse split, and try to find buyers of the shares at the "new" higher price. Fewer shares/same amount of money in the till, with LOTS of room to issue more shares down the road, if needed, until they can get some decent upfronts. Plus that way, management gets to keep their jobs, and Cor gets to keep it's technology, without giving it away at fire sale prices. Everybody wins, opps, forgot the shareholders.......often they don't in reverse splits.
Of course if Cor can keep having days like the last few, then by the time they need funds, the share price will be high enough to issue new shares without the reverse split. I just don't see them issue new shares for under a buck, but that is just my opinion.....
There is no easy way, GFP has been saying it for a while, the money to continue HAS to come from somewhere. Nice upfronts would be optimal, imo.
Wondered when we would see you again freto, it's been on a rocket.....Glad I kept some (I never pick the high in Cor!)
Take Care.
A lot of these are popping today, so it is a good day to get good news, unlike most days in Jan.
It will be interesting to see what kind of legs it has. Could be strong ones if the US market starts getting new attention.
Take Care.
Thanks Surf, I won't mess up when it comes time to sell, this time around
OT- Tina Marie, Love the Myspace page, my first, sad but true!
Take Care.
Thanks Surf, Showing up .11 to .90 in pre-market, .83-.90. no volume yet.
Take Care.
Hello Asu, Hope you are well.
See, as soon as I start selling in the mid 50's, cor takes off:0)
I have been taking some COR off the table for a while now, selling into the strength, the same way I was buying into the weakness.
Please don't crucify me, but you might want to think about unloading some of your recent purchases, at some point, if cor keeps rising.
That way you have locked in your lower cost per share on the huge position you would be left with. Sure you might leave some on the table, but you also might avoid a wipe out should cor get negative RD results and be forced into a reverse split. (I have not really ever thought that they would sell out, I have always thought they would just reverse split and do a new offering....but that is just my opinion. They have reverse split before.)
Anyway, I am heading out and won't be able to read any posts about being a traitor for selling a bunch of COR, but I did nicely off the investment, for me, and I hope it keeps rising for those heavily invested. (I still own a good bit, but not nearly what I once did.)
Take Care.
Hello Surf, I was wondering if you still have COR on your radar?
Nice pop this morning on no news that I can find, 150k shares in first minutes.
I have been selling for a week or two, off and on, into the recent strength. I had a ton of shares I got by buying into the weakness it had in the 4th quarter 07.
Anyway, I was curious on your take of the stock if you still follow it.
Take Care.
Hello surf, hope you are doing well.
any interest in snus again?
i have them trading about 60-70% discount of their announced, expected, jan cash of .88 share.
Take Care.
Thanks surf, agreed. Last time i had it, it was only for a few days, and looks like this one is going off the radar. too many others out there.
take care.
Thanks catty, this one bounces around like a ping pong ball, insiders buying near this level, so maybe its fortunes will turn soon. I added more since my last post, small buys on dips. (3.69 and 3.58, and now 3.52)
Thanks again.
Hello catty, Added a little more on this dip.
Take Care.
hello surf, this one is nearing its 52 week low, and i was wondering if you still keep tabs on it?
it closed at .47, just now small after hours trade went through at .50.
news a couple days ago.
take care.
2 Days old news: Genta says FDA extends review time for cancer drug Genasense
Mon Jan 14, 2008 8:20am EST
http://www.reuters.com/article/marketsNews/idUKWNAS634720080114?rpc=44
Genta Inc (GNTA.O: Quote, Profile, Research) said the U.S. Food and Drug Administration has extended the review of the appeal the company had filed against the health regulator's refusal to approve its cancer treatment, Genasense.
Genta now expects a final decision on the drug later in the current quarter. It had earlier expected a final decision in the fourth quarter of 2007.
The biopharmaceutical company said this review is related to the use of the drug, combined with chemotherapy, in patients with relapsed or refractory chronic lymphocytic leukemia, a kind of blood cancer. (Reporting by Varsha Tickoo in Bangalore; Editing by Pratish Narayanan)
hello catty, hummm, another women telling me to listen to my wife, what are the odds
i am starting to think that i might just dollar cost average this stock, adding a little each day/week on dips.
i can't remember being so unsure about making a commitment to a stock, must be the female angle! ha.
take care.
hello catty, well, maybe third time will be a charm. Just nibbled some on this dip.
just asked my wife if she thought there would be much of a market for this within the women she knows/has known, and she thinks for sure......so.......
take care.
Will check em out, thx eom.
Thanks for keeping this one going as long as you did surf.
I looked at it, but didn't have any when the buyout news came.
I am mostly cash right now, buying a little SNUS last couple days......thinking of getting a little more.....
Take Care.
Nice Chart Dew! It must be nice to see your hard work coming to be, well, on the road to everything you hoped it would.
Glad I listened.
Thanks and Take Care.
Hello gfp, of course if the rd news is bad, cor goes down, unless it is already built into the price on that day
often with cor, imo, the time to sell is the time leading up to an "event." considering that most biotechs fail, or do not become blockbusters, this makes sense to me.
of course if the news is good, then maybe we would be sorry we sold early.....)
how many times have we seen cor not move up much on "good" news? many times, as the action often takes place on the anticipation..... (buy the rumor, sell the news.)
anyway, the stock sure seemed strong to me on this day, even if it closes down a bit, in days past it could have tanked with that limited action.
Take Care.
Hello laddadg, Agreed, you did great on those shares at .52 as I am showing those as the low for the day so far.
I couldn't believe how it took the pounding I gave it on such an overall low volume day. I have seen many cor days when it will drop on orders in the hundreds of shares, and today nearly no drop on tens of thousands.
It will be interesting to see how it holds up in the days ahead. More volume will tell the tale.
Take Care.
Hello asu, Happy New Year to you too. Glad to hear you are in the green for 08. Tough market for sure so far this year.
I sold a little COR this morning into obvious strength. (I was buying pretty good in the 40's, not asuhowe good, but pretty good
Anyway, take care.
Hello jerrydylan, The stock is showing strength in here.
I have sold 30k shares of the 40k total shares traded this morning, and the stock barely moved. Six 5k limit orders, first 4 at .56, last 2 at .55, all filled quickly, in seconds, and the last 5k were filled with shares not showing on my Level II. All the sells were between 10:49 and 11:03.
Just mm's lapping them up to resell in the coming days at higher prices would be my first guess.
I have seen days in COR where 30k shares worth of sells would have tanked it. (freto mentioned cor yesterday afternoon, something about, will it hold, or some such thing, so that crowd may be buying.....)
Of course now that I am about to post, the bid dropped to .53..... Took 16% on this mornings, still tons long, just waiting for better days.
Take Care.
OT- gfp, I pm'ed you 24 slides.
Hello gfp, I have 26 slides created on my machine Nov. 5th. I think some of these may be what you are looking for. I don't know if I can email attachments on Ihub, as I haven't tried it before, but I will give it a shot.
Take Care.
PS, Aiming, can you delete naked's most recent posts? (or repost without the personal attacks?)
Top 10 Biotech Buzz Stocks for This Year
(Contains IDIX mention, found on HotBio board by surf1944)
http://www.thestreet.com/_yahoo/newsanalysis/biotech/10398390.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
Hello Aiming, I am with you on MEMY, since the 1 million share insider purchase a month or two ago.
Also, Aiming, I was wondering if you were still following SNUS? During their last conference call in Nov. they said that they estimated that they would have about .88/share in cash with no debt as of Dec 31st, 2007. Currently trading, with little interest, near 52 week low, around .44. (i think the 52 week low is around .40)
I see it as relatively low risk trade, for cheapo, hammered, small stock. Their cash estimate was enough to last until 3rd quarter, 2009, again, their estimate during last conference call from Nov. That would give them all of 2008, with 9 months to spare, before running out of funds. That's a lot of time to come back from low .40's, imo, at least for a bounce or two. Again, just for a trade.
Anyway, hope you are doing well and hoping for good COR RD results.
Take Care.
IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
http://biz.yahoo.com/prnews/071231/aqm003.html?.v=36
Monday December 31, 8:30 am ET
IRVINE, Calif., Dec. 31 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI - News) today announced that as part of the Company's recent decision to evaluate strategic alternatives, the Company initiated discussions with sanofi-aventis. Following this, sanofi-aventis has notified the Company of its decision to discontinue participation in the development of UVIDEM, its investigational therapy being studied for the treatment of melanoma, with all rights to the product reverting to the Company.
In connection with this decision, the Company announced it expects to restructure, which it anticipates will involve staff reductions in the Company's workforce and a review of the assets and costs associated with products under development. The Company's restructuring plan is expected to be finalized and approved by the Company's Board of Directors during the first quarter of 2008. The Company expects to retain a core team in key functional areas and, as part of the Company's previously announced strategic initiatives, will continue to evaluate the UVIDEM clinical program, which recently completed Phase 2 studies with promising results.
The Company believes that these decisions have the following potential benefits:
-- IDM Pharma now has full rights to its product candidates including
mifamurtide (L-MTP-PE), IDM-2101 and UVIDEM
-- The anticipated restructuring is expected to enable the Company to
significantly reduce its infrastructure and operating expenses
-- The restructured company may be a more attractive partner in any
potential strategic transaction going forward
"These decisions provide the company with increased flexibility in our assessment of strategic options," said Timothy P. Walbert, president and chief executive of IDM Pharma. "In addition, we are continuing to pursue potential regulatory approvals for mifamurtide (L-MTP-PE) and the possible further clinical development of IDM-2101."
The Company will work with sanofi-aventis to conclude the UVIDEM collaboration within the three month timeframe prescribed in their agreement. As of September 30, 2007, sanofi-aventis owned approximately 7.9% of the Company's outstanding common stock.
About UVIDEM
UVIDEM is a therapeutic specific immunostimulant developed to date by IDM Pharma in partnership with sanofi-aventis. UVIDEM consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. UVIDEM has been administered to 143 patients in clinical development.
About IDM Pharma
IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.
For more information about the company and its products, visit http://www.idm-pharma.com.
Forward-Looking Statements
This press release and the presentation described in this press release include forward-looking statements that reflect management's current views of future events including statements regarding the strategic alternatives available to the Company, the Company's anticipated restructuring, benefits that may be derived from the discontinued development of UVIDEM and the anticipated restructuring, regulatory approval for L-MTP-PE, further development plans for the Company's clinical products and the timing for conclusion of the UVIDEM collaboration. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to identify and complete any strategic transaction that would benefit the Company and its stockholders on a timely basis, if at all, the possibility that the discontinuation of development of UVIDEM will not provide expected benefits and may have a negative effect on regulatory approvals for UVIDEM, the possibility that the Company may not obtain regulatory approval for L-MTP-PE and the possibility that delays in the anticipated restructuring will have a negative impact on the Company's operating results,. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products, whether the cash resources of the Company will be sufficient to fund operations as planned, including any further clinical trials of any of the Company's product candidates, and the Company's dependence on intellectual property. These factors and others affecting the Company's business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended September 30, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
--------------------------------------------------------------------------------
Source: IDM Pharma, Inc.
CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
Thursday December 20, 6:43 am ET
http://biz.yahoo.com/prnews/071220/neth037.html?.v=35
BRANFORD, Conn., Dec. 20 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, today announced the appointment of Sean Cassidy, as Vice President and Chief Financial Officer effective January 1, 2008. CuraGen also announced today that David M. Wurzer will step down from his position effective January 1, 2008 to pursue other opportunities, but will remain with the Company through March 2008, as an advisor to the Company.
"We are pleased to welcome Sean to the CuraGen team," commented Timothy Shannon, President and Chief Executive Officer. "We believe that Sean's accounting and financial expertise in the life sciences sector, combined with his historical knowledge of CuraGen, will be beneficial as we advance our development pipeline towards commercialization."
Dr. Shannon further commented, "On behalf of the entire board and employees of CuraGen, I would like to thank Dave Wurzer for his more than 10 years of service to CuraGen during which he made substantial contributions across the organization. Dave will continue to work with CuraGen over the next few months to ensure a smooth and effective transition."
Previously, Mr. Cassidy served as Corporate Controller of 454 Life Sciences Corporation (454) since September 2002. Mr. Cassidy joined 454 when it was a development stage company and supported its growth into a successful commercial entity. During this time, Mr. Cassidy assisted 454 in a private round of financing in 2003, entering into a comprehensive License, Supply and Distribution Agreement with Roche Applied Science in 2005 and in the acquisition of 454 by Roche Applied Science in 2007. Prior to joining 454, Mr. Cassidy served as Manager of Financial Planning at CuraGen Corporation from August 2001 to September 2002. Mr. Cassidy also spent over eight years at Deloitte & Touche LLP's Hartford office in the audit practice. During this time Mr. Cassidy served both public and private companies in various industries; advising these clients on public and private securities offerings, mergers and acquisition due diligence reviews and annual and quarterly reporting requirements under the Securities and Exchange Commission's rules and regulations.
Mr. Cassidy earned both his Master of Business Administration degree and his Bachelor of Science in Accounting from the University of Connecticut in 2000 and 1992, respectively. Mr. Cassidy is a certified public accountant in the State of Connecticut.
About CuraGen
CuraGen Corporation (Nasdaq: CRGN - News) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including the histone deacetylase inhibitor, belinostat, and the antibody-drug conjugate, CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit www.curagen.com.
Safe Harbor
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the benefits to be achieved as a result of Mr. Cassidy's hiring may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific, regulatory or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CRGN-G
Contacts:
Glenn Schulman, PharmD
Director of Investor Relations
gschulman@curagen.com
(888) 436-6642
For what it is worth I added some this morning at 1.01. Just no interest in it right now.
Take Care.
Thanks Ogclip, I had the header shut off, but now that I see it, it does look pretty good....At least if you are long.....
Take Care....
Yup. I have been adding as well, since the news of the most recent 1 million share insider purchase.
Take Care.
Nice early morning .10 pop in memy. I don't show any news and I was wondering if you had anything? Only 110k shares traded so far, so it might just be pent up demand.
Take Care.
hello catty, do you know how that drug is selling, or what kinds on funds are rolling into bpax right now?
I know it said 40 million possible, but I wondered how the drug was selling and thought you might know off the top of your head.
Take Care.